Pioglitazone
- Generic Name
- Pioglitazone
- Brand Names
- Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N2O3S
- CAS Number
- 111025-46-8
- Unique Ingredient Identifier
- X4OV71U42S
- Background
Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medicatio...
- Indication
Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.
- Associated Conditions
- Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance
- Conditions
- Interventions
- First Posted Date
- 2005-04-18
- Last Posted Date
- 2008-04-25
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 48
- Registration Number
- NCT00108615
- Locations
- 🇺🇸
Central Arkansas Veterans HCS, Little Rock, Arkansas, United States
Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-04-01
- Last Posted Date
- 2010-09-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1440
- Registration Number
- NCT00106808
- Locations
- 🇺🇦
Local Institution, Simferopol, Ukraine
Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2004-12-22
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 362
- Registration Number
- NCT00099853
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes
- Conditions
- First Posted Date
- 2004-11-22
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 230
- Registration Number
- NCT00097279
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States
Insulin Resistance Intervention After Stroke Trial
- Conditions
- Interventions
- First Posted Date
- 2004-09-22
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Yale University
- Target Recruit Count
- 3876
- Registration Number
- NCT00091949
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸University of South Alabama, Mobile, Alabama, United States
🇺🇸Shanti Clinical Trials (NINDS-CRC site), Colton, California, United States
Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)
- Conditions
- Interventions
- First Posted Date
- 2004-07-05
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 701
- Registration Number
- NCT00086515
Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)
- Conditions
- Interventions
- First Posted Date
- 2003-07-03
- Last Posted Date
- 2018-04-06
- Target Recruit Count
- 247
- Registration Number
- NCT00063622
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Washington, Seattle, Washington, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)
- Conditions
- First Posted Date
- 2001-04-26
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 300
- Registration Number
- NCT00015626
- Locations
- 🇺🇸
Cornell University, New York, New York, United States
Treatment of Nonalcoholic Steatohepatitis With Pioglitazone
- Conditions
- First Posted Date
- 2001-03-26
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 30
- Registration Number
- NCT00013598
- Locations
- 🇺🇸
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.